Authors:
Address: Departamento de Procesos y Tecnología, Universidad Autónoma Metropolitana-Cuajimalpa, Mexico City, Mexico. alara@correo.cua.uam.mx
Journal:

Publication:

abstract

Plasmid DNA (pDNA) is the base for promising DNA vaccines and gene therapies against many infectious, acquired, and genetic diseases, including HIV-AIDS, Ebola, Malaria, and different types of cancer, enteric pathogens, and influenza. Compared to conventional vaccines, DNA vaccines have many advantages such as high stability, not being infectious, focusing the immune response to only those antigens desired for immunization and long-term persistence of the vaccine protection. Especially in developing countries, where conventional effective vaccines are often unavailable or too expensive, there is a need for both new and improved vaccines. Therefore the demand of pDNA is expected to rise significantly in the near future. Since the injection of pDNA usually only leads to a weak immune response, several milligrams of DNA vaccine are necessary for immunization protection. Hence, there is a special interest to raise the product yield in order to reduce manufacturing costs. In this chapter, the different stages of plasmid DNA production are reviewed, from the vector design to downstream operation options. In particular, recent advances on cell engineering for improving plasmid DNA production are discussed.

Related Articles
Review Engineering of bacterial strains and vectors for the production of plasmid DNA.
Appl Microbiol Biotechnol. 2009
Review Engineering of bacterial strains and vectors for the production of plasmid DNA.
Bower DM, Prather KL. Appl Microbiol Biotechnol. 2009 Apr; 82(5):805-13. Epub 2009 Feb 10.
Review Upstream processing of plasmid DNA for vaccine and gene therapy applications.
Recent Pat Biotechnol. 2008
Review Upstream processing of plasmid DNA for vaccine and gene therapy applications.
Tejeda-Mansir A, Montesinos RM. Recent Pat Biotechnol. 2008; 2(3):156-72.
Review Purification of plasmids for gene therapy and DNA vaccination.
Biotechnol Annu Rev. 2001
Review Purification of plasmids for gene therapy and DNA vaccination.
Prazeres DM, Monteiro GA, Ferreira GN, Diogo MM, Ribeiro SC, Cabral JM. Biotechnol Annu Rev. 2001; 7:1-30.
Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.
J Virol. 2007
Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.
Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, Garcia-Hand D, Abdullah R, Braun R, Montefiori DC, et al. J Virol. 2007 May; 81(10):5257-69. Epub 2007 Feb 28.
Review Biomedical application of plasmid DNA in gene therapy: a new challenge for chromatography.
Biotechnol Genet Eng Rev. 2010
Review Biomedical application of plasmid DNA in gene therapy: a new challenge for chromatography.
Sousa F, Passarinha L, Queiroz JA. Biotechnol Genet Eng Rev. 2010; 26:83-116.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster